Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
Ann Rheum Dis
.
2021 Mar;80(3):e37.
doi: 10.1136/annrheumdis-2020-217864.
Epub 2020 Jun 5.
Authors
Jérôme Avouac
1
,
Paolo Airó
2
,
Nicolas Carlier
3
,
Marco Matucci-Cerinic
4
,
Yannick Allanore
5
Affiliations
1
Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France
[email protected]
.
2
Department of Rheumatology and Clinical Immunology Service, Spedali Civili di Brescia, Brescia, Italy.
3
Université de Paris, Service de Pneumologie, Hôpital Cochin, AP-HP.CUP, Paris, France.
4
Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
5
Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France.
PMID:
32503849
DOI:
10.1136/annrheumdis-2020-217864
No abstract available
Keywords:
inflammation; rituximab; scleroderma; systemic.
Publication types
Letter
Comment
MeSH terms
COVID-19*
Humans
Pneumonia*
Rituximab / therapeutic use
Scleroderma, Systemic* / complications
Scleroderma, Systemic* / drug therapy
Substances
Rituximab